News

Pancreatic Cancer Conference, London 2026 – Cancer Research UK

Registration is now open for the Pancreatic Cancer Conference organised by Cancer Research UK. The event will take place in London from 7–9 July....

ALPANC researchers publish study protocol comparing 3D modeling versus conventional CT

3D-PANC study protocol: Is three-dimensional imaging technology superior to computed tomography for assessing the response to neoadjuvant treatment in patients with borderline or locally advanced pancreatic adenocarcinoma? This study focuses on improving the...

New potential therapeutic target for pancreatic cancer identified by ALIPANC researchers

The study by Parejo-Alonso et al. identifies PPAR-δ as a critical transcription factor mediating pancreatic cancer cell adaptation to microenvironmental stress. Normally involved in lipid metabolism, PPAR-δ is overexpressed in pancreatic tumors and, under metabolic...

ALIPANC researchers develop a new therapeutic combination in preclinical models of pancreatic cancer.

This study conducted by researchers from Vigo presents an innovative sequential therapeutic strategy against pancreatic ductal adenocarcinoma, one of the most lethal cancers due to its stromal barrier that prevents drug penetration. The novelty lies in the biphasic...

Merry Christmas!

GNAS-ddPCR: A Cost-Effective First Step in the Diagnosis of Pancreatic Cystic Neoplasms, Developed by Researchers from the ALIPANC Group

The analysis of GNAS mutations using ddPCR in fluid obtained through endoscopic ultrasound–guided fine-needle aspiration has proven to be a useful and cost-effective diagnostic tool for evaluating mucinous pancreatic cystic neoplasms. This technique can be applied...

Researchers from ALIPANC describe a triple therapy targeting key proteins in KRAS signaling that induces complete tumor regression in a mouse model

A study led by the Experimental Oncology Group at the Spanish National Cancer Research Centre (CNIO) has described a triple-combination therapy for pancreatic cancer. The work has been published in the prestigious journal Proceedings of the National Academy of...

ALIPANC Election Results

On December 2, 2025, ALIPANC held its Extraordinary General Assembly to ratify the results of the electoral process for the Management Committee. The online voting system ensured transparency and participation, reaching 58% of elegible voting groups. Management...

IV ALIPANC Solidarity Gala Dinner: Science and Solidarity Against Pancreatic Cancer

On November 21, ALIPANC held its 4th Solidarity Gala Dinner at the Élkar restaurant in Madrid, coinciding with World Pancreatic Cancer Day. The main goal was to raise funds to boost pancreatic cancer research, a disease that remains one of the greatest challenges in...

Next ALIPANC Online Seminar – December 11th, 15:00 CET

Title: Results of VIRAGE trial: a randomized Phase IIb, open-label, study of Nab-Paclitaxel and Gemcitabine with/without intravenous VCN-01 in Patients with Metastatic Pancreatic Cancer Speaker: Dr. Manel Cascalló, CEO of Theriva Biologics   About Dr. Manel...

ALIPANC Election Results

On December 2, 2025, ALIPANC held its Extraordinary General Assembly to ratify the results of the electoral process...

read more